Vanguard Group
ASND icon

Vanguard Group’s Ascendis Pharma A/S ASND Stock Holding History

Vanguard Group’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,462
Closed -$357K – 4528
2022
Q3 		$357K Buy
+3,462
New +$328K ﹤0.01% 4305

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Vanguard Group's ASND Position: Q4 2022 in Review

Vanguard Group sold out of Ascendis Pharma A/S (ASND) in Q4 2022, closing a stake of 3,462 shares — an estimated $357K sold.

Vanguard Group first reported a position in ASND in Q3 2022 and held it in 1 quarter. The position peaked at $357K in Q3 2022. 187 funds tracked by Wall St. Rank hold ASND as of Q4 2022.

  • Vanguard Group reported no remaining Ascendis Pharma A/S position as of Q4 2022 after selling out during the quarter.
  • Vanguard Group sold 3,462 Ascendis Pharma A/S shares in Q4 2022, an estimated $357K.
  • Vanguard Group first reported a position in Ascendis Pharma A/S in Q3 2022 and held it in 1 quarter.
  • Vanguard Group's Ascendis Pharma A/S position peaked at $357K in Q3 2022.
  • 187 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2022.

Based on Vanguard Group's 13F filing for Q4 2022, filed 10 Feb 2023.